The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
503 - We were granted a new indication based on a pivotal study. However, some datapoints in the published study, in a peer-review journal, are not found in the TMA. We would like to know if it is "off label" for our reps to speak to those data points since it is extra data points in our studied population for which we have an indication? Can they use the reprint and speak to those results?
-
Drug rep activities do not fall under the scope of the PAAB. Whether the content can appear within advertising materials is a matter that falls under the scope of the PAAB code. We can assess whether the specific content from this study would be acceptable in advertising in the context of a formal PAAB opinion submission (see our fee schedule). The number of variables that require consideration causes this question not to be amenable to a general answer.
